Getinge AB (GETI-B) Fair Value & Analysis
Healthcare · SE · Market cap 56.8B SEK
Fair value as of: Jul 15, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Jul 15, 2026, revised from kr 192.70 to kr 192.14 (−0.3%) since Jun 24, 2026. Share price +19.6% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 176.27 – kr 232.50 · fair‑value band kr 111.36 – kr 244.32 · the kr 232.00 price screens above the kr 192.14 fair value. As of Jul 15, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Getinge AB (GETI-B) currently trades at kr 232.00, while our model-based Fair Value estimate is kr 192.14, implying the stock looks roughly 17.2% overvalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Getinge AB generated revenue of 34.1B SEK at a net margin of 6.9%. Revenue declined 10.5% year over year. It earns a return on equity of 7.7%. Net debt stands at 7.5B SEK. Fundamentals as of Jul 15, 2026
Our scenario range runs from kr 111.36 (bear case) to kr 244.32 (bull case); at kr 232.00, the current price sits within that range. The share trades near its 52-week high and 35% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -17%, GETI-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 15, 2026. TTM = trailing twelve months.
About the company
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Getinge AB reported revenue of kr 35.0B in FY2025 versus kr 27.0B in FY2021, a compound +6.6%/yr. Reported net income was kr 2.3B in FY2025, compounding −6.6%/yr from FY2021.
Is GETI-B fairly valued? → Check now
Recent news
- Global Medical Ventilators Market Report 2025-2030 Just Released; Comprehensive Profiles of Getinge, Drägerwerk, Philips, Medtronic, and Res
- Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Membe
- [Latest] Global Neonatal Intensive Care Respiratory Devices Market Size/Share Worth USD 5.7 Billion by 2035 at a 10.5% CAGR: Healthcare Fore
- Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EWL | €75.46 | €37.29 | -51% |
| Siemens Healthineers AG SEMHF | $39.91 | $48.29 | +21% |
| DexCom, Inc DXCM | $68.92 | $38.95 | -43% |
| GE HealthCare Technologies Inc GEHC | $60.64 | $65.03 | +7% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
| Koninklijke Philips N.V PHG | $26.98 | $12.54 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Getinge AB (GETI-B) undervalued?
What is the fair value of GETI-B?
What is the quality score of GETI-B?
What is the revenue of Getinge AB (GETI-B)?
What is the net profit margin of GETI-B?
Does Getinge AB pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Getinge AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.